Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J.-C.
Right arrow Articles by Wang, W.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.-C.
Right arrow Articles by Wang, W.-Y.
Related Articles
Right arrowRelated Correspondence
Right arrowRelated Reply
Journal of Clinical Oncology, Vol 21, Issue 4 (February), 2003: 631-637
© 2003 American Society for Clinical Oncology

Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Positive Effect on Overall and Progression-Free Survival

Jin-Ching Lin, Jian-Sheng Jan, Chen-Yi Hsu, Wen-Miin Liang, Rong-San Jiang, Wen-Yi Wang

From the Departments of Radiation Oncology and Otorhinolaryngology, Taichung Veterans General Hospital; Department of Public Health, China Medical College; Department of Basic Medicine, Hung Kuang Institute of Technology, Taichung; and Institute of Clinical Medicine, College of Medicine, National Yang-Ming University, Taipei, Taiwan.

Address reprint requests to Jin-Ching Lin, MD, PhD, Department of Radiation Oncology, Taichung Veterans General Hospital, Taiwan, No. 160, Sec. 3, Taichung-Kang Rd., Taichung, 407 Taiwan, email: jclin{at}mail.vghtc.gov.tw.

Purpose: Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumor. This randomized phase III trial compared concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in patients with advanced NPC.

Patients and Methods: From December 1993 to April 1999, 284 patients with 1992 American Joint Committee on Cancer stage III to IV (M0) NPC were randomly allocated into two arms. Similar dosage and fractionation of RT was administered in both arms. The investigational arm received two cycles of concurrent chemotherapy with cisplatin 20 mg/m2/d plus fluorouracil 400 mg/m2/d by 96-hour continuous infusion during the weeks 1 and 5 of RT. Survival analysis was estimated by the Kaplan-Meier method and compared by the log-rank test.

Results: Baseline patient characteristics were comparable in both arms. After a median follow-up of 65 months, 26.2% (37 of 141) and 46.2% (66 of 143) of patients developed tumor relapse in the CCRT and RT-alone groups, respectively. The 5-year overall survival rates were 72.3% for the CCRT arm and 54.2% for the RT-only arm (P = .0022). The 5-year progression-free survival rates were 71.6% for the CCRT group compared with 53.0% for the RT-only group (P = .0012). Although significantly more toxicity was noted in the CCRT arm, including leukopenia and emesis, compliance with the combined treatment was good. The second cycle of concurrent chemotherapy was refused by nine patients and was delayed for >= 1 week for another nine patients. There were no treatment-related deaths in either arm.

Conclusion: We conclude that CCRT is superior to RT alone for patients with advanced NPC in endemic areas.

Supported by grants from the National Science Council (NSC86-2314-B-075A-022 and NSC87-2314-B-075A-002) and Taichung Veterans General Hospital (TCVGH-887102C and TCVGH-897101C), Taiwan.


Related Correspondence

  • Cisplatin and Fluorouracil Concurrent to Radiotherapy in Nasopharyngeal Cancer: Is the Schedule Compatible?
    Lisa Licitra, Paolo Bossi, Laura Locati, and Franco Zunino
    JCO 2004 22: 377 [Full Text]

Related Reply

  • In Reply:
    Jin-Ching Lin and Jian-Sheng Jan
    JCO 2004 22: 377-378 [Full Text]


This article has been cited by other articles:


Home page
Arch Otolaryngol Head Neck SurgHome page
A. C. Vlantis, R. K. Y. Tsang, B. K. H. Yu, M. K. M. Kam, M. C. F. Tong, P. S. Y. Lo, and C. Andrew van Hasselt
Nasopharyngectomy and Surgical Margin Status: A Survival Analysis
Arch Otolaryngol Head Neck Surg, December 1, 2007; 133(12): 1296 - 1301.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Glynne-Jones and P. Hoskin
Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?
J. Clin. Oncol., November 20, 2007; 25(33): 5281 - 5286.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. K. Salama, T. Y. Seiwert, and E. E. Vokes
Chemoradiotherapy for Locally Advanced Head and Neck Cancer
J. Clin. Oncol., September 10, 2007; 25(26): 4118 - 4126.
[Full Text] [PDF]


Home page
JCOHome page
S.-f. Leung, B. Zee, B. B. Ma, E. P. Hui, F. Mo, M. Lai, K.C. A. Chan, L. Y.S. Chan, W.-h. Kwan, Y.M. D. Lo, et al.
Plasma Epstein-Barr Viral Deoxyribonucleic Acid Quantitation Complements Tumor-Node-Metastasis Staging Prognostication in Nasopharyngeal Carcinoma
J. Clin. Oncol., December 1, 2006; 24(34): 5414 - 5418.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
S.-C. Chan, T.-C. Yen, S.-H. Ng, C.-Y. Lin, H.-M. Wang, C.-T. Liao, K.-H. Fan, and J. T.-C. Chang
Differential Roles of 18F-FDG PET in Patients with Locoregional Advanced Nasopharyngeal Carcinoma After Primary Curative Therapy: Response Evaluation and Impact on Management
J. Nucl. Med., September 1, 2006; 47(9): 1447 - 1454.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. C. Buckner, K. V. Ballman, J. C. Michalak, G. V. Burton, T. L. Cascino, P. J. Schomberg, R. B. Hawkins, B. W. Scheithauer, H. M. Sandler, R. S. Marks, et al.
Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials
J. Clin. Oncol., August 20, 2006; 24(24): 3871 - 3879.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. S. C. Wong, R. A. Soo, J. J. Lu, K. S. Loh, K. S. Tan, W. S. Hsieh, T. P. Shakespeare, E. T. Chua, H. L. Lim, and B. C. Goh
Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma
Ann. Onc., July 1, 2006; 17(7): 1152 - 1157.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Zhang, C. Zhao, P.-J. Peng, L.-X. Lu, P.-Y. Huang, F. Han, and S.-X. Wu
Phase III Study Comparing Standard Radiotherapy With or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results
J. Clin. Oncol., November 20, 2005; 23(33): 8461 - 8468.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. W.M. Lee, W.H. Lau, S. Y. Tung, D. T.T. Chua, R. Chappell, L. Xu, L. Siu, W.M. Sze, T.W. Leung, J. S.T. Sham, et al.
Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group
J. Clin. Oncol., October 1, 2005; 23(28): 6966 - 6975.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Wee, E. H. Tan, B. C. Tai, H. B. Wong, S. S. Leong, T. Tan, E. T. Chua, E. Yang, K. M. Lee, K. W. Fong, et al.
Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety
J. Clin. Oncol., September 20, 2005; 23(27): 6730 - 6738.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q.-T. Le, C. D. Jones, T.-K. Yau, H. A. Shirazi, P. H. Wong, E. N. Thomas, B. K. Patterson, A. W.M. Lee, and J. L. Zehnder
A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma
Clin. Cancer Res., August 15, 2005; 11(16): 5700 - 5707.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. H. Cheng and A. T. Huang
Comments on Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: A Mist of Mysterious Results
J. Clin. Oncol., April 20, 2005; 23(12): 2864 - 2865.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. T. C. Chan, S. F. Leung, R. K. C. Ngan, P. M. L. Teo, W. H. Lau, W. H. Kwan, E. P. Hui, H. Y. Yiu, W. Yeo, F. Y. Cheung, et al.
Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma
J Natl Cancer Inst, April 6, 2005; 97(7): 536 - 539.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. T.T. Chua, J. Ma, J. S.T. Sham, H.-Q. Mai, D. T.K. Choy, M.-H. Hong, T.-X. Lu, and H.-Q. Min
Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials
J. Clin. Oncol., February 20, 2005; 23(6): 1118 - 1124.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J.A. Langendijk, Ch.R. Leemans, J. Buter, J. Berkhof, and B.J. Slotman
The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published Literature
J. Clin. Oncol., November 15, 2004; 22(22): 4604 - 4612.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
M. Kawashima, N. Fuwa, M. Myojin, K. Nakamura, T. Toita, S. Saijo, N. Hayashi, H. Ohnishi, N. Shikama, M. Kano, et al.
A Multi-institutional Survey of the Effectiveness of Chemotherapy Combined with Radiotherapy for Patients with Nasopharyngeal Carcinoma
Jpn. J. Clin. Oncol., October 1, 2004; 34(10): 569 - 583.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. T.C. Chan, B. B.Y. Ma, Y.M. D. Lo, S.F. Leung, W.H. Kwan, E. P. Hui, T. S.K. Mok, M. Kam, L. S. Chan, S. K.W. Chiu, et al.
Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA
J. Clin. Oncol., August 1, 2004; 22(15): 3053 - 3060.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. L.W. Kwong, J. S.T. Sham, G. K.H. Au, D. T.T. Chua, P. W.K. Kwong, A. C.K. Cheng, P.M. Wu, M. W.M. Law, C. C.H. Kwok, C.C. Yau, et al.
Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: A Factorial Study
J. Clin. Oncol., July 1, 2004; 22(13): 2643 - 2653.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J.-C. Lin, W.-Y. Wang, K. Y. Chen, Y.-H. Wei, W.-M. Liang, J.-S. Jan, and R.-S. Jiang
Quantification of Plasma Epstein-Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma
N. Engl. J. Med., June 10, 2004; 350(24): 2461 - 2470.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Licitra, P. Bossi, L. Locati, and F. Zunino
Cisplatin and Fluorouracil Concurrent to Radiotherapy in Nasopharyngeal Cancer: Is the Schedule Compatible?
J. Clin. Oncol., January 15, 2004; 22(2): 377 - 377.
[Full Text] [PDF]


Home page
JCOHome page
J.-C. Lin and J.-S. Jan
In Reply:
J. Clin. Oncol., January 15, 2004; 22(2): 377 - 378.
[Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
K. Isobe, H. Kawakami, T. Uno, S. Yasuda, T. Aruga, N. Ueno, T. Kawata, and H. Ito
Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: is Intergroup Study 0099 Feasible in Japanese Patients?
Jpn. J. Clin. Oncol., October 1, 2003; 33(10): 497 - 500.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
L. Licitra
Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation?
Ann. Onc., April 1, 2003; 14(4): 508 - 509.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online